We are delighted to announce that our latest paper has been published in Nature Reviews Bioengineering: Down to Business. The paper dives...

MUVON Therapeutics was featured by Nature as one of the companies leading the way with innovative treatments for stress urinary incontinence, showcasing the immense potential in women's health advancements. Despite women driving 80% of healthcare spending, women's health receives less than 1% of biopharma funding. Deana Mohr, CEO of MUVON Therapeutics, highlights the issue: "Investors often see women’s health as a niche 'wellness' sector rather than an area of high unmet medi

MUVON's latest article was recently published in Leading Opinions Gynäkologie & Geburtshilfe, dealing with the topic of stress urinary...

First in Human (FIH) trial results of MUVON's regenerative therapy for the treatment of stress urinary incontinence are now officially published in the International Urogynecology Journal. Deana Mohr, CEO: “We are thrilled with peer-review publication of our first-in-human phase I clinical trial demonstrating that the implantation of autologous muscle precursor cells for the treatment of Stress Urinary Incontinence in women is safe and feasible.” John F Coelho, Medical

Informative article published in BioInsights , written by our CSO Jenny Prange and our innovation manager Beatrix Rauch Schmid . This viewpoint gives a short summary about what needs to be considered to transfer an autologous celltherapy from bench to bedside and what automation challenges could arise during future development. Read the full article here .

Abstract: Urinary incontinence affects a large number of patients, and the cost of treatment continues to rise with the demographic...